Vimarsana
Biggest News Aggregation in the World

Anders Kronborg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anders Kronborg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anders Kronborg Today - Breaking & Trending Today

The Ecosystem: European Innovation Council uncouples grant and equity funding for start-ups - Vimarsana News

The Ecosystem: European Innovation Council uncouples grant and equity funding for start-ups

From 2024, start-ups will no longer be able to bid for grant-first funding under the European Innovation Council (EIC) Accelerator programme. Instead, this option will be integrated into the programme’s blended finance offer, in a recognition that many more applicants would like to separate decisions about grant funding and equity investment.

Resolutions from Aqilion Annual General Meeting 2023 - Vimarsana News

Resolutions from Aqilion Annual General Meeting 2023

Resolutions from Aqilion Annual General Meeting 2023Helsingborg, June 1, 2023 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance with the proposals presented. For more detailed information on the content of the resolutions, please see the full notice to the An...

LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States - Vimarsana News

LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States

LEO Pharma A/S, a global leader in medical dermatology, today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective

Brian Hilberdink Names President of LEO Pharma Inc. United States - Vimarsana News

Brian Hilberdink Names President of LEO Pharma Inc. United States

LEO Pharma A/S announced it has appointed Brian Hilberdink new executive vice president and president of Madison-based LEO Pharma Inc.

LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis - Vimarsana News

LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis

LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.